What Interpace Biosciences does

Interpace Biosciences, Inc. (OTCQX: IDXG) is a publicly traded molecular diagnostics company headquartered in Parsippany, New Jersey, that commercializes proprietary laboratory tests used by specialty physicians and medical centers to evaluate indeterminate thyroid nodules. The company operates through its core subsidiary Interpace Diagnostics, which runs a CLIA-certified clinical laboratory that performs two commercialized assays in combination: ThyGeNEXT, a next-generation sequencing-based mutation profiling test that identifies genetic mutations highly indicative of thyroid cancer when traditional cytology is inconclusive, and ThyraMIRv2, a proprietary microRNA expression classifier that helps physicians identify thyroid nodules least likely to be malignant. The franchise addresses a defined clinical decision point — the indeterminate thyroid nodule — where the tests provide evidence-based risk stratification intended to reduce unnecessary surgeries and avoid missed cancers.

The business model is a usage-based clinical laboratory services model: healthcare providers order tests through the company's physician portal, specimens are processed at the company's CLIA-certified laboratory, and Interpace is reimbursed by Medicare, private insurance, and direct billing for each test performed. Following the May 2025 discontinuation of the PancraGEN pancreatic cyst test (specimens no longer accepted after May 2, 2025), the company derives 100% of revenue from its thyroid testing franchise. The go-to-motion is enterprise-style direct engagement with endocrinologists, endocrine surgeons, and hospital systems in the U.S. and internationally, supported by a physician portal, sales coverage, and an investor-facing communications program.

Operationally, the company has executed a multi-year strategic repositioning: it sold the Interpace Pharma Solutions biopharma services business to Flagship Biosciences in August 2022, exited pancreatic testing in 2025, fully paid off all outstanding debt in Q4 2025, and converted all preferred stock to common stock in January 2026 — at which point Ampersand Capital Partners held approximately 50% and 1315 Capital Partners approximately 34% of the approximately 27.7 million pro forma basic shares outstanding. With growing thyroid volume, expanding gross margins (65% in Q1 2026, up from 59% pro forma), and a debt-free balance sheet, management has signaled intent to uplist to Nasdaq in 2026.

Name

Interpace Biosciences

Legal name

Interpace Biosciences, Inc.

Website

https://interpace.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Interpace Biosciences is a public molecular diagnostics company that operates a CLIA-certified clinical laboratory providing the ThyGeNEXT and ThyraMIRv2 tests to endocrinologists, endocrine surgeons, and medical centers for risk stratification of indeterminate thyroid nodules, reimbursed by Medicare and private insurers.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• Molecular diagnostic tests
• Thyroid cancer diagnostics
• Next generation sequencing
• MicroRNA expression testing
• Clinical laboratory services

Headquarters

HQ city

Hamilton

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Thyroid Diagnostic Testing Services: Interpace Biosciences generates revenue through clinical laboratory testing services, specifically its ThyGeNEXT and ThyraMIRv2 molecular diagnostic tests for thyroid cancer. Revenue comes from Medicare, insurance reimbursements, and direct billing for molecular diagnostic testing services provided to healthcare providers evaluating patients with indeterminate thyroid nodules. The company discontinued its PancraGEN product line in May 2025 and now generates 100% of revenue from thyroid testing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Interpace Biosciences, through its subsidiary Interpace Diagnostics, provides evidence-based molecular diagnostic testing services that risk-stratify cytologically indeterminate thyroid nodules. Its two commercialized tests, ThyGeNEXT (NGS-based mutation profiling) and ThyraMIR v2 (a proprietary microRNA classifier), are used together to help physicians determine whether nodules are likely malignant, reducing unnecessary surgeries and missed cancers. Following the May 2025 discontinuation of PancraGEN, 100% of revenue is generated by the thyroid testing franchise.

Product overview

Interpace Biosciences provides molecular diagnostic tests for early cancer diagnosis through its subsidiary Interpace Diagnostics. The company offers two commercialized molecular tests: ThyGeNEXT (a Next Generation Sequencing-based mutation profile that identifies cancer-indicative mutations from thyroid nodules when cytology is indeterminate) and ThyraMIR v2 (a proprietary microRNA-based classifier used in combination with ThyGeNEXT). Following the May 2025 discontinuation of PancraGEN, the company now focuses exclusively on thyroid diagnostics, providing specialized testing services to specialty physicians and medical centers throughout the U.S. and internationally.

Differentiator

Problem solved

Functional benefit

Brands

• Interpace Diagnostics: Subsidiary that develops and commercializes molecular diagnostic tests including ThyGeNEXT and ThyraMIRv2 for thyroid cancer diagnosis

Products and services

• ThyGeNEXT A Next Generation Sequencing (NGS)-based mutation profile performed by Interpace's CLIA-certified laboratory that identifies genetic mutations from thyroid nodules highly indicative of thyroid cancer when traditional cytology results are indeterminate. Used in combination with ThyraMIR v2 and ordered by specialty physicians and medical centers through the Interpace physician portal.
• ThyraMIR v2 A proprietary microRNA-based gene-expression classifier used together with ThyGeNEXT to assist physicians in identifying thyroid nodules least likely to be malignant when cytology is indeterminate. Performed as part of Interpace's combined NGS plus microRNA testing workflow for specialty physicians and medical centers.

Quantifiable outcome

• Gross margin expanded to 65% in Q1 2026 from 59% year-over-year on pro forma basis
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

One partnership is on record.

• Flagship BiosciencesminorOthers · 1 August 2022Interpace sold its Interpace Pharma Solutions division to Flagship Biosciences in August 2022, divesting its biopharma services business to focus exclusively on thyroid diagnostics.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Veracyte: Veracyte's Afirma Genomic Sequencing Classifier is the leading molecular test for evaluating indeterminate thyroid nodules, directly competing with Interpace's ThyGeNEXT and ThyraMIRv2 in the same indication and customer base of endocrinologists and endocrine surgeons.
• Castle Biosciences: Castle Biosciences commercializes molecular diagnostic tests that guide treatment decisions in cancers including thyroid (ThyroSeq-v2 alternative profiles), using a similar specialty-physician GTM motion and proprietary genomic/molecular classifier approach.

Broad incumbents

• NeoGenomics: NeoGenomics is a specialty oncology-focused clinical laboratory offering molecular and genetic testing services, including in thyroid and other solid tumors. It is a broader incumbent with substantially greater scale than Interpace.
• Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with a portfolio of gene-based tests across oncology, including hereditary cancer risk assessment. It competes with Interpace in the broader specialty-physician oncology testing channel.
• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory companies in the U.S., offering a broad menu of molecular and genetic tests, including endocrine and oncology panels, and has the scale and payer relationships to compete with Interpace's thyroid franchise.
• Laboratory Corporation of America (LabCorp): LabCorp is a leading global clinical laboratory network that offers a comprehensive menu of molecular diagnostic and esoteric tests, including in oncology and endocrinology, and competes with Interpace via broad physician relationships and integrated lab services.
• Exact Sciences: Exact Sciences is a leading molecular diagnostics company best known for Cologuard, with an expanding oncology portfolio that includes liquid biopsy and treatment-selection tests. It is a broader incumbent in molecular cancer diagnostics with significantly greater scale.

Emerging players

• Natera: Natera is a molecular diagnostics company specializing in cell-free DNA and genetic testing across oncology, women's health, and organ health. While not focused on thyroid nodules, it competes in the molecular diagnostics space serving specialty physicians.
• BioReference Laboratories (Opko Health): BioReference, an Opko Health subsidiary, is a full-service clinical laboratory offering specialty molecular diagnostics including oncology panels, serving physicians and health systems with an esoteric testing menu that overlaps with Interpace's specialty oncology channel.
• Guardant Health: Guardant Health is a leading precision oncology company specializing in liquid biopsy tests for cancer detection and monitoring. While primarily focused on blood-based oncology testing, it competes with Interpace in the molecular diagnostics market serving oncologists and specialists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/idxgbiosciences
• Xx.com/InterpaceBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interpace Biosciences